174 related articles for article (PubMed ID: 29570629)
1. Constructing TC-1-GLUC-LMP2 Model Tumor Cells to Evaluate the Anti-Tumor Effects of LMP2-Related Vaccines.
Sun L; Hao Y; Wang Z; Zeng Y
Viruses; 2018 Mar; 10(4):. PubMed ID: 29570629
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of a multiepitope plasmid DNA encoding T and B lymphocyte epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a vaccine in mice.
Li W; Chen Q; Lin Q; Lv Y; Feng J; Liu J; Xu W; Chen S; Zhu X; Zhang L
Protein Pept Lett; 2013 Oct; 20(10):1136-43. PubMed ID: 23688153
[TBL] [Abstract][Full Text] [Related]
3. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
4. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
Bollard CM; Straathof KC; Huls MH; Leen A; Lacuesta K; Davis A; Gottschalk S; Brenner MK; Heslop HE; Rooney CM
J Immunother; 2004; 27(4):317-27. PubMed ID: 15235393
[TBL] [Abstract][Full Text] [Related]
5. Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agent.
Lin X; Chen S; Xue X; Lu L; Zhu S; Li W; Chen X; Zhong X; Jiang P; Sename TS; Zheng Y; Zhang L
Cell Mol Immunol; 2016 Jul; 13(4):492-501. PubMed ID: 25864917
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
[TBL] [Abstract][Full Text] [Related]
7. Specific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination.
Wang Z; Yang S; Zhou L; Du H; Mo W; Zeng Y
Sci China Life Sci; 2011 Mar; 54(3):263-6. PubMed ID: 21416326
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo.
Lin MC; Lin YC; Chen ST; Young TH; Lou PJ
BMC Cancer; 2017 Jan; 17(1):18. PubMed ID: 28056887
[TBL] [Abstract][Full Text] [Related]
10. [Sequence analysis of the CTL epitopes in transmembrane region of latent membrane protein 2 of Epstein-Barr virus derived from nasopharyngeal carcinoma cells].
Zhang NH; Zhang XS; Li J; Zhang RH; Gao YF; Zeng MS
Ai Zheng; 2006 May; 25(5):566-9. PubMed ID: 16687075
[TBL] [Abstract][Full Text] [Related]
11. Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.
Zheng Y; Parsonage G; Zhuang X; Machado LR; James CH; Salman A; Searle PF; Hui EP; Chan AT; Lee SP
Cancer Immunol Res; 2015 Oct; 3(10):1138-47. PubMed ID: 25711537
[TBL] [Abstract][Full Text] [Related]
12. A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.
Fox CP; Haigh TA; Taylor GS; Long HM; Lee SP; Shannon-Lowe C; O'Connor S; Bollard CM; Iqbal J; Chan WC; Rickinson AB; Bell AI; Rowe M
Blood; 2010 Nov; 116(19):3695-704. PubMed ID: 20671118
[TBL] [Abstract][Full Text] [Related]
13. Immune response of mice to a latency membrane protein 2 multiepitope antigen of Epstein-Barr virus applied as DNA vaccine and/or peptide vaccine.
Li W; Chen Q; Chen H; Rao P; Xue X; Chen S; Zhu S; Zhang L
Acta Virol; 2013; 57(1):51-8. PubMed ID: 23530824
[TBL] [Abstract][Full Text] [Related]
14. A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.
Taylor GS; Jia H; Harrington K; Lee LW; Turner J; Ladell K; Price DA; Tanday M; Matthews J; Roberts C; Edwards C; McGuigan L; Hartley A; Wilson S; Hui EP; Chan AT; Rickinson AB; Steven NM
Clin Cancer Res; 2014 Oct; 20(19):5009-22. PubMed ID: 25124688
[TBL] [Abstract][Full Text] [Related]
15. [Dendritic cells transfected with recombinant adenovirus Ad5F35-LMP2 induces LMP2 specific immunity mediated by cytotoxic T lymphocytes in vitro].
Mo WN; Zhou L; Wang Z; Tang AZ; Huang GW; Zeng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Aug; 22(4):254-6. PubMed ID: 19105335
[TBL] [Abstract][Full Text] [Related]
16. Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies.
Micheletti F; Guerrini R; Formentin A; Canella A; Marastoni M; Bazzaro M; Tomatis R; Traniello S; Gavioli R
Eur J Immunol; 1999 Aug; 29(8):2579-89. PubMed ID: 10458773
[TBL] [Abstract][Full Text] [Related]
17. EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.
McLaughlin LP; Gottschalk S; Rooney CM; Bollard CM
Methods Mol Biol; 2017; 1532():255-265. PubMed ID: 27873282
[TBL] [Abstract][Full Text] [Related]
18. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
Perez EM; Foley J; Tison T; Silva R; Ogembo JG
Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
[TBL] [Abstract][Full Text] [Related]
19. [T cells recognizing EBV-epitopes arose in co-culture of peripheral blood mononuclear cells from EB-infected patients and dendritic cells loaded with LMP2-mixed peptides].
Xing YP; Cen XN; Tong CR; Gu JY; Cai P; Tao XY; Jin X; Zhu P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):392-6. PubMed ID: 18426672
[TBL] [Abstract][Full Text] [Related]
20. Expression of HPV6b L1/EBV LMP2 multiepitope and immunogenicity in mice.
Zhu S; Xue X; Liu J; Lu L; Zhao P; Wang J; Li W; Zhang L
Acta Biochim Biophys Sin (Shanghai); 2010 Aug; 42(8):515-21. PubMed ID: 20705592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
